Occlutech obtains European CE mark approval for its LAA Occluder

Schaffhausen, Switzerland -Occlutech, a leading innovator of implants to treat structural heart disease,today announced that it has obtained European CE Mark approval for its Left Atrial Appendix, (LAA), occluder. The device is a specifically designed implant for theminimally invasive closure of the LAA, a procedure that minimizes the risk of strokes in patients suffering from atrial fibrillation…

We use cookies to customize content for your viewing and for analytics. If you continue to browse this website, we will assume that you are happy to receive all our cookies. Learn more